Clinical data | |
---|---|
Routes of administration | Subcutaneous |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C43H50N8O5S |
Molar mass | 790.98 g·mol−1 |
3D model ( JSmol) | |
| |
|
Relamorelin ( INN, USAN) (developmental code names RM-131, BIM-28131, BIM-28163) is a synthetic peptide, centrally penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) which is under development by Allergan pharmaceuticals for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa. [1] [2] [3] It is a pentapeptide and an analogue of ghrelin with improved potency and pharmacokinetics. [1] [2] In humans, relamorelin produces increases in plasma growth hormone, prolactin, and cortisol levels, [2] [4] and, like other GHSR agonists, increases appetite. [3] As of June 2015, relamorelin is in phase II clinical trials for diabetic gastroparesis and constipation. [5] The United States Food and Drug Administration (FDA) has granted Fast Track designation to relamorelin for diabetic gastroparesis. [6] The development of the drug is uncertain as the most recent mention of it was in a 2019 SEC filing from the drug manufacturer lists the drug's expected launch year as 2024, but not in subsequent filings or press releases. [7] [8]